ICCM vs. BWAY, OM, SKIN, CATX, SI, MGRM, TLSI, INGN, NNOX, and INFU
Should you be buying IceCure Medical stock or one of its competitors? The main competitors of IceCure Medical include Brainsway (BWAY), Outset Medical (OM), Beauty Health (SKIN), Perspective Therapeutics (CATX), Shoulder Innovations (SI), Monogram Orthopaedics (MGRM), TriSalus Life Sciences (TLSI), Inogen (INGN), Nano-X Imaging (NNOX), and InfuSystem (INFU). These companies are all part of the "medical equipment" industry.
IceCure Medical vs. Its Competitors
IceCure Medical (NASDAQ:ICCM) and Brainsway (NASDAQ:BWAY) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.
Brainsway has higher revenue and earnings than IceCure Medical. IceCure Medical is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.
IceCure Medical has a beta of 0.31, suggesting that its stock price is 69% less volatile than the S&P 500. Comparatively, Brainsway has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500.
0.6% of IceCure Medical shares are held by institutional investors. Comparatively, 30.1% of Brainsway shares are held by institutional investors. 2.4% of IceCure Medical shares are held by insiders. Comparatively, 19.0% of Brainsway shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
In the previous week, IceCure Medical had 13 more articles in the media than Brainsway. MarketBeat recorded 13 mentions for IceCure Medical and 0 mentions for Brainsway. IceCure Medical's average media sentiment score of 0.42 beat Brainsway's score of 0.00 indicating that IceCure Medical is being referred to more favorably in the media.
IceCure Medical currently has a consensus target price of $2.64, indicating a potential upside of 163.53%. Brainsway has a consensus target price of $18.00, indicating a potential upside of 18.19%. Given IceCure Medical's higher possible upside, analysts clearly believe IceCure Medical is more favorable than Brainsway.
Brainsway has a net margin of 11.60% compared to IceCure Medical's net margin of -317.62%. Brainsway's return on equity of 8.97% beat IceCure Medical's return on equity.
Summary
Brainsway beats IceCure Medical on 11 of the 16 factors compared between the two stocks.
Get IceCure Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for ICCM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ICCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
IceCure Medical Competitors List
Related Companies and Tools
This page (NASDAQ:ICCM) was last updated on 10/7/2025 by MarketBeat.com Staff
